{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:32:30Z","timestamp":1793151150647,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computational Biology and Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.compbiolchem.2026.109252","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T15:31:38Z","timestamp":1784388698000},"page":"109252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Predicting target interactomes and prognostic biomarkers of Quizartinib in acute myeloid leukemia: An integrative network pharmacology and In-silico approach"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8653-3685","authenticated-orcid":false,"given":"Akshata P.","family":"Hebballi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2257-2718","authenticated-orcid":false,"given":"Girish A.","family":"Hampannavar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iranna","family":"Gatibyali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manas","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.compbiolchem.2026.109252_bib1","article-title":"Cancer management and research midostaurin in acute myeloid leukemia: an evidence-based review and patient selection midostaurin in acute myeloid leukemia","author":"Abbas","year":"2019","journal-title":"Evid. -Based Rev. Patient Sel."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib2","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/1946703","article-title":"Exploring prognostic biomarkers of acute myeloid leukemia to determine its most effective drugs from the FDA-approved list through molecular docking and dynamic simulation","volume":"2023","author":"Alom","year":"2023","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ajh.24974","article-title":"Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia","volume":"93","author":"Altman","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.24198\/ijcb.v2i1.46322","article-title":"Molecular interaction analysis and visualization of protein-ligand docking using biovia discovery studio Visualizer","volume":"2","author":"Baroroh","year":"2023","journal-title":"Indones. J. Comput. Biol. (IJCB"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.14383","article-title":"Advances and challenges in Quizartinib-based FLT3 inhibition for acute myeloid leukemia: mechanisms of resistance and prospective combination therapies","author":"Bruzzese","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.14383","article-title":"Advances and challenges in Quizartinib-based FLT3 inhibition for acute myeloid leukemia: mechanisms of resistance and prospective combination therapies","author":"Bruzzese","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib7","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/17474086.2021.1969911","article-title":"Safety of FLT3 inhibitors in patients with acute myeloid leukemia","volume":"14","author":"Cerchione","year":"2021","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib8","article-title":"Global, national, and regional burden of acute myeloid leukemia among 60\u201389 years-old individuals: insights from a study covering the period 1990\u20132019","volume":"11","author":"Chen","year":"2023","journal-title":"Front. Public. Health"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib9","first-page":"1","article-title":"Analysis of action of 1,4-naphthoquinone scaffold-derived compounds against acute myeloid leukemia based on network pharmacology, molecular docking and molecular dynamics simulation","volume":"14","author":"Chen","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib10","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.287627","article-title":"It takes two to tango: allogeneic stem cell transplantation and FLT3 tyrosine kinase inhibitor therapy","author":"Cornelissen","year":"2025","journal-title":"Haematologica 110 19031905"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib12","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.3324\/haematol.2018.205385","article-title":"Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5- And hypoxia-dependent upregulation of AXL","volume":"104","author":"Dumas","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib13","first-page":"1","article-title":"Acute myeloid leukemia (AML)","author":"Estey","year":"2012","journal-title":"Leuk. Relat. Disord. Integr. Treat. Approaches"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/CMAR.S196568","article-title":"Profile of quizartinib for the treatment of adult patients with relapsed\/refractory FLT3-ITD-positive acute myeloid leukemia: evidence to date","volume":"12","author":"Fletcher","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc.2015.18","article-title":"The kinome \u201cat large\u201d in cancer","volume":"16","author":"Fleuren","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106983","article-title":"The magnitude of CXCR4 signaling regulates resistance to quizartinib in FLT3\/ITD+ cells via RUNX1","volume":"124","author":"Fukuda","year":"2023","journal-title":"Leuk. Res."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/pro.3730","article-title":"RCSB protein data bank: enabling biomedical research and drug discovery","volume":"29","author":"Goodsell","year":"2020","journal-title":"Protein Sci."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib18","doi-asserted-by":"crossref","first-page":"7924","DOI":"10.1182\/blood-2024-212095","article-title":"Outcomes of acute myeloid leukemia patients aged 60 years and above: an analysis of SEER data","volume":"144","author":"Gopishetty","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HS9.0000000000000262","article-title":"Acute myeloid leukemia","volume":"3","author":"Haferlach","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1655005","article-title":"Metabolic reprogramming and immune regulation in acute myeloid leukemia","volume":"16","author":"Hao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1179\/1607845413Y.0000000139","article-title":"Angiogenesis and acute myeloid leukemia","volume":"19","author":"Haouas","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1478-811X-11-97","article-title":"Targeting the PDGF signaling pathway in tumor treatment","volume":"11","author":"Heldin","year":"2013","journal-title":"Cell. Commun. Signal."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: The next paradigm in drug discovery","author":"Hopkins","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/09537104.2024.2354833","article-title":"Application of the cellular thermal shift assay (CETSA) to validate drug target engagement in platelets","volume":"35","author":"Howes","year":"2024","journal-title":"Platelets"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/bs.mie.2016.05.002","article-title":"Cell-binding assays for determining the affinity of protein\u2013protein interactions: technologies and considerations","volume":"580","author":"Hunter","year":"2016","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-025-18547-0","article-title":"silico approaches unveil the mechanism of action of Eclipta prostrata against acute myeloid leukemia","volume":"15","author":"Islam","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib27","doi-asserted-by":"crossref","first-page":"W345","DOI":"10.1093\/nar\/gkz424","article-title":"PrankWeb: a web server for ligand binding site prediction and visualization","volume":"47","author":"Jendele","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbad014","article-title":"Comprehensive assessment of nine target prediction web services: which should we choose for target fishing?","volume":"24","author":"Ji","year":"2023","journal-title":"Brief. Bioinforma."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-024-13286-3","article-title":"Proteomic and metabolomic exploration in relapse acute myeloid leukemia bone marrow supernatant combined with genetic characteristics","volume":"24","author":"Ji","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcell.2021.796757","article-title":"Decoding the mechanism of Shen Qi Sha Bai decoction in treating acute myeloid leukemia based on network pharmacology and molecular docking","volume":"9","author":"Jia","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-12-19","article-title":"Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms","volume":"12","author":"Kampa-Schittenhelm","year":"2013","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/ijms23094694","article-title":"Mutated KIT tyrosine kinase as a novel molecular target in acute myeloid leukemia","volume":"23","author":"Katagiri","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2024.104253","article-title":"Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitors","volume":"137","author":"Khamari","year":"2024","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkt1207","article-title":"STITCH 4: integration of protein-chemical interactions with user data","volume":"42","author":"Kuhn","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib36","first-page":"659","article-title":"Network pharmacology: a systems-based paradigm-drivenmulti-target drug discovery & development","volume":"15","author":"Kumari","year":"2025","journal-title":"Eur. J. Cardiovasc. Med."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib37","doi-asserted-by":"crossref","DOI":"10.62958\/j.cjap.2025.007","article-title":"Targeting FLT3 mutations in acute myeloid leukemia: the role of Quizartinib in precision medicine. Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi =","author":"Kumbhare","year":"2025","journal-title":"Chin. J. Appl. Physiol."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0959-8049(02)80598-6","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"38","author":"Levitzki","year":"2002","journal-title":"European journal cancer (Oxford England 1990)"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105389","article-title":"Network pharmacology prediction and molecular docking-based strategy to explore the potential mechanism of Huanglian Jiedu decoction against sepsis","volume":"144","author":"Li","year":"2022","journal-title":"Comput. Biol. Med."},{"issue":"1","key":"10.1016\/j.compbiolchem.2026.109252_bib40","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal. Transduct. Target. Ther. 2023"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib41","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/sj.leu.2404245","article-title":"Phosphoinositide 3-kinase\/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia","volume":"20","author":"Martelli","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.932353","article-title":"RET signaling pathway and RET inhibitors in human cancer","volume":"12","author":"Regua","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib43","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0268-960X(03)00024-9","article-title":"Receptor tyrosine kinases in normal and malignant haematopoiesis","volume":"17","author":"Reilly","year":"2003","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.compbiolchem.2026.109252_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12014-020-09290-x","article-title":"Using phosphoproteomics data to understand cellular signaling: a comprehensive guide to bioinformatics resources","volume":"17","author":"Savage","year":"2020","journal-title":"Clin. Proteom. 2020"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib45","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1182\/blood-2012-01-402545","article-title":"Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3\/ITD AML","volume":"120","author":"Sexauer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib46","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib47","first-page":"1","article-title":"Identification of hub genes and immune-related pathways in acute myeloid leukemia: insights from bioinformatics and experimental validation","volume":"15","author":"Shan","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib48","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/2159-8290.CD-15-0060","article-title":"Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 \u201cGatekeeper\u201d F691L mutation with PLX3397","volume":"5","author":"Smith","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib49","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2008.26","article-title":"Contributions of the Raf\/MEK\/ERK, PI3K\/PTEN\/Akt\/mTOR and Jak\/STAT pathways to leukemia","volume":"22","author":"Steelman","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib50","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/blood-2005-03-1062","article-title":"Multiple roles of Rap1 in hematopoietic cells: complementary versus antagonistic functions","volume":"106","author":"Stork","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib51","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib52","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1007\/s12094-023-03125-5","article-title":"Exploring underlying mechanism of artesunate in treatment of acute myeloid leukemia using network pharmacology and molecular docking","volume":"25","author":"Tao","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib53","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib54","first-page":"1","article-title":"Leukemia in older adults: global, national, and regional disease burden patterns during 1990\u20132019 and forecasted trends to 2030","author":"Wei","year":"2025","journal-title":"Med. Adv."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-018-0675-4","article-title":"FLT3 inhibitors in acute myeloid leukemia","volume":"11","author":"Wu","year":"2018","journal-title":"J. Hematol. & Oncol."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib56","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.compbiolchem.2026.109252_bib57","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6195174","article-title":"Effects of Qinghuang powder on acute myeloid leukemia based on network pharmacology, molecular docking, and in vitro experiments","volume":"2021","author":"Zeng","year":"2021","journal-title":"Evid. -Based Complement. Altern. Med."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib58","article-title":"Network pharmacology: a new approach for Chinese herbal medicine research","author":"Zhang","year":"2013","journal-title":"Evid. -Based Complement. Altern. Med."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib59","first-page":"1","article-title":"Network pharmacology, molecular docking, and experimental validation-based approach to explore the mechanism of action of ginsenoside Rh4 on acute myeloid leukemia cells","volume":"43","author":"Zhang","year":"2026","journal-title":"Med. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.109252_bib60","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2147\/DDDT.S198950","article-title":"Quizartinib (AC220): a promising option for acute myeloid leukemia","volume":"13","author":"Zhou","year":"2019","journal-title":"Drug. Des. Dev. Ther."}],"container-title":["Computational Biology and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476927126003798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476927126003798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:42:27Z","timestamp":1793148147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476927126003798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":60,"alternative-id":["S1476927126003798"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2026.109252","relation":{},"ISSN":["1476-9271"],"issn-type":[{"value":"1476-9271","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting target interactomes and prognostic biomarkers of Quizartinib in acute myeloid leukemia: An integrative network pharmacology and In-silico approach","name":"articletitle","label":"Article Title"},{"value":"Computational Biology and Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2026.109252","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109252"}}